^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    volrustomig (MEDI5752)

    i
    Other names: MEDI5752, MEDI-5752, MEDI 5752
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    27d
    Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (clinicaltrials.gov)
    P3, N=800, Recruiting, AstraZeneca | Trial primary completion date: Feb 2027 --> Nov 2026
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    volrustomig (MEDI5752)
    2ms
    eVOLVE-01: Volrustomig Priming Regimens Exploratory Phase II Platform Study (clinicaltrials.gov)
    P2, N=120, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    carboplatin • pemetrexed • volrustomig (MEDI5752)
    3ms
    NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=490, Recruiting, AstraZeneca | Trial completion date: Dec 2029 --> May 2030 | Trial primary completion date: Dec 2029 --> May 2030
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • oleclumab (MEDI9447) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)
    3ms
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=60, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    volrustomig (MEDI5752)
    4ms
    NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=490, Recruiting, AstraZeneca | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2028 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • oleclumab (MEDI9447) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)
    5ms
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, AstraZeneca
    New P2 trial • Combination therapy • Metastases
    |
    volrustomig (MEDI5752)
    5ms
    eVOLVE-01: Volrustomig Priming Regimens Exploratory Phase II Platform Study (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, AstraZeneca | Trial completion date: Jan 2028 --> Oct 2026
    Trial completion date • Combination therapy
    |
    carboplatin • pemetrexed • volrustomig (MEDI5752)
    6ms
    FTIH: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=401, Active, not recruiting, MedImmune LLC | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • volrustomig (MEDI5752)
    6ms
    eVOLVE-01: Volrustomig Priming Regimens Exploratory Phase II Platform Study (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, AstraZeneca
    New P2 trial • Combination therapy
    |
    carboplatin • pemetrexed • volrustomig (MEDI5752)
    7ms
    DESTINY-Lung03: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (clinicaltrials.gov)
    P1, N=248, Recruiting, AstraZeneca | N=168 --> 248
    Enrollment change • IO biomarker • Metastases
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    7ms
    MEDI5752 in Japanese Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2024 --> Mar 2025
    Trial completion date • Metastases
    |
    volrustomig (MEDI5752)
    7ms
    Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer. (PubMed, J Gynecol Oncol)
    Only some phase I results in such development is published so far and no full report on this is available till now. This effort will try to record the facts and chain of events which actually occurred in inventing and bringing it in phase III trial.
    Review • Journal
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    volrustomig (MEDI5752)
    8ms
    MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Recruiting, Presage Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    8ms
    Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=531, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
    |
    Avastin (bevacizumab) • carboplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine • prednisone • leucovorin calcium • datopotamab deruxtecan (DS-1062a) • saruparib (AZD5305) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    8ms
    PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Presage Biosciences
    New P1 trial
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    9ms
    FTIH: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=401, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • volrustomig (MEDI5752)
    10ms
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | Trial completion date: May 2023 --> Mar 2026
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)
    10ms
    MEDI5752 in Japanese Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, AstraZeneca | Trial primary completion date: Mar 2024 --> Aug 2023
    Trial primary completion date • Metastases
    |
    volrustomig (MEDI5752)
    10ms
    Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov)
    P2, N=357, Recruiting, AstraZeneca | Phase classification: P1b/2 --> P2 | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    10ms
    NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=490, Recruiting, AstraZeneca | N=350 --> 490
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • oleclumab (MEDI9447) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)
    10ms
    Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)
    P2, N=260, Recruiting, AstraZeneca | N=180 --> 260 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Immunomodulating • Metastases
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    11ms
    eVOLVE-HNSCC: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P3, N=1145, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    volrustomig (MEDI5752)
    12ms
    TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1; Phase classification: P1b --> P1 | N=232 --> 321
    Combination therapy • Enrollment change • Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    1year
    MEDISARC-SBRT: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Institut Claudius Regaud
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    volrustomig (MEDI5752)
    1year
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=600, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    1year
    Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03). (ASCO-GI 2024)
    Previously, confirmed ORRs of 50% and 43% were reported with T-DXd + 5-fluorouracil (5-FU) and T-DXd + capecitabine (Cap), respectively, in the second-line or later setting in part 1 of DG-03. The protocol was amended to add an additional arm in part 2 and a new part 3, which will investigate T-DXd in combination with a fluoropyrimidine and volrustomig (MEDI5752), a PD-1/CTLA-4 bispecific antibody, in pts with HER2+ and HER2-low (IHC 2+/ISH− or IHC 1+) GC...In arm F of part 2, pts with previously untreated HER2+ GC will be treated with T-DXd + investigator’s choice of 5-FU or Cap + pembrolizumab...Secondary endpoints include safety, duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and immunogenicity. Clinical trial information: NCT04379596.
    Clinical • P1/2 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • volrustomig (MEDI5752)
    1year
    Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=240, Recruiting, AstraZeneca | N=80 --> 240
    Enrollment change • Metastases
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    1year
    eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P3, N=900, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • PD-L1 negative • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)
    1year
    A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=179, Recruiting, MedImmune LLC | Phase classification: P1b --> P1 | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Dec 2025 --> Aug 2027
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Lenvima (lenvatinib) • Inlyta (axitinib) • volrustomig (MEDI5752)
    1year
    eVOLVE-HNSCC: A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P3, N=1145, Not yet recruiting, AstraZeneca
    New P3 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    volrustomig (MEDI5752)
    1year
    NeoCOAST-2: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=350, Recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Dec 2028 | Trial primary completion date: Mar 2026 --> Dec 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • oleclumab (MEDI9447) • volrustomig (MEDI5752) • falbikitug (AZD0171) • monalizumab (IPH2201)
    1year
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=600, Not yet recruiting, AstraZeneca
    New P3 trial • Combination therapy
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    1year
    MEDISARC-SBRT: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    volrustomig (MEDI5752)
    1year
    eVOLVECervical: Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (clinicaltrials.gov)
    P3, N=1000, Recruiting, AstraZeneca
    New P3 trial • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PGR expression
    |
    volrustomig (MEDI5752)
    over1year
    TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1b; Trial completion date: Feb 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Jan 2026
    Combination therapy • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    over1year
    eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov)
    P3, N=900, Not yet recruiting, AstraZeneca
    New P3 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • PD-L1 negative • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)
    over1year
    Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03 (ESMO 2023)
    This trial is evaluating T-DXd alone or in combination with durvalumab (durva) or MEDI5752 (a PD-1/CTLA-4 bispecific antibody) with or without chemotherapy in pts with unresectable/metastatic, HER2-OE, nonsquamous NSCLC...In part 1 (enrollment completed), pts with disease progression after 1 or 2 lines of systemic therapy in the recurrent/metastatic setting receive T-DXd monotherapy or T-DXd + durva in combination with cisplatin, carboplatin, or pemetrexed...The primary endpoint is the frequency of adverse events (AEs) and serious AEs (SAEs) with T-DXd + durva + chemotherapy (part 1) or T-DXd + MEDI5752 ± chemotherapy (part 3). Secondary endpoints include confirmed objective response rate, duration of response, disease control rate, progression-free and overall survival, pharmacokinetics, and immunogenicity in all arms as well as the frequency of AEs and SAEs with T-DXd monotherapy (part 1).
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    EGFR mutation • HER-2 overexpression • EML4-ALK fusion • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • volrustomig (MEDI5752)
    over1year
    MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) (ESMO 2023)
    Volrustomig with lenvatinib is also being evaluated in 1L aRCC (NCT04522323). Table: 1883MO Efficacy DCO 25Jan2023 M750 M500 Total IMDC Total IMDC F I/P F I/P Response-evaluable, N 32 8 24 33 12 21 ORR, n (%) 15 (46.9) 2 (25) 13 (54.2) 15 (45.5) 7 (58.3) 8 (38.1) CR, n (%) 3 (9.4) 1 (12.5) 2 (8.3) 2 (6.1) 2 (16.7) 0 (0) DCR, n (%) 28 (87.5) 6 (75) 22 (91.7) 23 (69.7) 11 (91.7) 12 (57.1) Progressive disease, n (%) 4 (12.5) – – 8 (24.2) – – mPFS (95% CI), months 11.1 (4.5–NE) – – 9.9 (3.9–NE) – – Per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. CI, confidence interval; CR, complete response; DCR, disease control rate; F, favorable; IMDC, International Metastatic RCC Database Consortium; I/P, intermediate/poor; mPFS, median progression free survival; NE, not estimable.
    Clinical • Metastases
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Lenvima (lenvatinib) • volrustomig (MEDI5752)
    over1year
    Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, AstraZeneca | N=120 --> 180
    Enrollment change • Combination therapy • Immunomodulating • Metastases
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    over1year
    MEDISARC-SBRT: Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Institut Claudius Regaud | Initiation date: May 2023 --> Sep 2023
    Trial initiation date • Combination therapy • Metastases
    |
    volrustomig (MEDI5752)
    over1year
    TAYLOR: MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. (clinicaltrials.gov)
    P2, N=102, Not yet recruiting, Institut Bergonié
    New P2 trial
    |
    volrustomig (MEDI5752)
    over1year
    MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov)
    P1, N=175, Active, not recruiting, AstraZeneca | N=258 --> 175 | Trial completion date: Mar 2026 --> May 2023 | Trial primary completion date: Mar 2026 --> May 2023
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • oleclumab (MEDI9447) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • danvatirsen (AZD9150)